Yusuke Katayama1, Takashi Oshima2, Kentaro Sakamaki3, Toru Aoyama1, Tsutomu Sato1, Katsuhiko Masudo4, Manabu Shiozawa5, Takaki Yoshikawa5, Yasushi Rino1, Toshio Imada6, Munetaka Masuda1. 1. Department of Surgery, Yokohama City University, Yokohama, Japan. 2. Department of Surgery, Yokohama City University, Yokohama, Japan ohshimatakashi@yahoo.co.jp. 3. Department of Biostatistics, Yokohama City University Medical Center, Yokohama, Japan. 4. Department of Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Japan. 5. Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan. 6. Department of Surgery, Saisei-kai Yokohama-shi Nanbu Hospital, Yokohama, Japan.
Abstract
BACKGROUND: Standard treatment for stage II/III gastric cancer is curative resection followed by adjuvant chemotherapy. However, the five-year survival remains unsatisfactory. Inhibin βA (INHBA) has been reported to be associated with cancer cell proliferation and chemoresistance. PATIENTS AND METHODS: We studied the clinical significance of INHBA gene expression in 134 patients with stage II/III gastric cancer who received adjuvant chemotherapy with S-1. INHBA expression of specimens of cancer tissue and adjacent normal mucosa was measured by quantitative real-time, reverse-transcription polymerase chain reaction (RT-PCR). RESULTS: INHBA expression levels were significantly higher in cancer tissue than in adjacent normal mucosa. High INHBA expression was associated with significantly poorer 5-year survival than was low expression. On multivariate analysis, INHBA expression was an independent prognostic factor. CONCLUSION: INHBA gene expression in gastric cancer tissue is considered a useful independent predictor of outcomes in patients with stage II/III gastric cancer who receive adjuvant chemotherapy with S-1. Copyright
BACKGROUND: Standard treatment for stage II/III gastric cancer is curative resection followed by adjuvant chemotherapy. However, the five-year survival remains unsatisfactory. Inhibin βA (INHBA) has been reported to be associated with cancer cell proliferation and chemoresistance. PATIENTS AND METHODS: We studied the clinical significance of INHBA gene expression in 134 patients with stage II/III gastric cancer who received adjuvant chemotherapy with S-1. INHBA expression of specimens of cancer tissue and adjacent normal mucosa was measured by quantitative real-time, reverse-transcription polymerase chain reaction (RT-PCR). RESULTS:INHBA expression levels were significantly higher in cancer tissue than in adjacent normal mucosa. High INHBA expression was associated with significantly poorer 5-year survival than was low expression. On multivariate analysis, INHBA expression was an independent prognostic factor. CONCLUSION:INHBA gene expression in gastric cancer tissue is considered a useful independent predictor of outcomes in patients with stage II/III gastric cancer who receive adjuvant chemotherapy with S-1. Copyright
Authors: J Jacob Wamsley; Manish Kumar; David F Allison; Sheena H Clift; Caitlyn M Holzknecht; Szymon J Szymura; Stephen A Hoang; Xiaojiang Xu; Christopher A Moskaluk; David R Jones; Stefan Bekiranov; Marty W Mayo Journal: Cancer Res Date: 2014-11-28 Impact factor: 12.701
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: Maya A Deyssenroth; Chris Gennings; Shelley H Liu; Shouneng Peng; Ke Hao; Luca Lambertini; Brian P Jackson; Margaret R Karagas; Carmen J Marsit; Jia Chen Journal: Environ Int Date: 2018-08-17 Impact factor: 9.621
Authors: Sihan Chen; G D Cao; Wu Wei; Lu Yida; He Xiaobo; Yang Lei; Chen Ke; Bo Chen; Mao Ming Xiong Journal: World J Surg Oncol Date: 2020-06-29 Impact factor: 2.754
Authors: Maciej Brązert; Wiesława Kranc; Mariusz J Nawrocki; Patrycja Sujka-Kordowska; Aneta Konwerska; Maurycy Jankowski; Ievgeniia Kocherova; Piotr Celichowski; Michal Jeseta; Katarzyna Ożegowska; Paweł Antosik; Dorota Bukowska; Mariusz T Skowroński; Małgorzata Bruska; Leszek Pawelczyk; Maciej Zabel; Hanna Piotrowska-Kempisty; Michał Nowicki; Bartosz Kempisty Journal: Mol Med Rep Date: 2020-01-27 Impact factor: 2.952